Novel Therapies and Clinical Trials

Novel Therapies & Clinical Trials


Current & Active Trials

Clinical Trial Using Immunotherapy For Dogs With Transitional Cell Carcinoma

Transitional cell carcinoma (TCC) is the most common type of bladder cancer in dogs.

cancer active transitional cell carcinoma TCC Mason TCC carcinoma Mason Active canine carcinoma canine bladder cancer bladder cancer in dogs bladder cancer active

Safety And Effectiveness Of Antibody Therapy For Dogs With Splenic Hemangiosarcoma

This trial evaluates the safety and effectiveness of an antibody therapy designed to inhibit VEGF and delay or prevent spread of hemangioscarcoma after surgery

cancer active Mason hemangiosarcoma Mason Cancer Studies Mason Active immunotherapy hemangiosarcoma canine hemangiosarcoma canine cancer cancer active

Re-directed Autologous T cell Therapy for drug resistant or refractory CD20+ B cell lymphoma

Immune cells (known as T cells) are taken from the peripheral blood, stimulated, expanded and genetically modified in the laboratory to express a surface receptor that recognizes B cells

cancer active Mason lymphoma Mason Cancer Studies Mason Active mason immunotherapy canine lymphoma canine cancer cancer b-cell malignancies B-cell lymphoma active

RNA-transfected CD40-B Cell Vaccines for Dogs With Newly Diagnosed Lymphoma

Determine whether a cell based vaccine can prevent the return of lymphoma after standard chemotherapy treatment.

cancer active Mason lymphoma Mason Cancer Studies Mason Active lymphoma immunotherapy canine lymphoma canine cancer cancer active

Interested in one of our clinical trials?

Past Trials